Literature DB >> 20679664

WTX mutations can occur both early and late in the pathogenesis of Wilms tumour.

Ryuji Fukuzawa1, Sarah K Holman, C W Chow, Ravi Savarirayan, Anthony E Reeve, Stephen P Robertson.   

Abstract

BACKGROUND: Somatic mutations in the X-linked tumour suppressor gene WTX have been observed in 6- 30% of sporadic cases of Wilms tumour. Germline mutations in the same gene cause the sclerosing skeletal dysplasia, osteopathia striata congenita with cranial sclerosis (OSCS). No evidence points towards a susceptibility to the development of tumours in individuals with OSCS, suggesting that there are unrecognised additional determinants that influence the phenotypic outcome associated with germline mutations in WTX. One explanation may be that a somatic mutation in WTX may need to occur late in tumour development to contribute to tumourigenesis.
METHODS: Here a panel of four sporadic Wilms tumours with associated nephrogenic rest tissue and characterised WTX and CTNNB1 mutations is studied to ascertain the temporal sequence of acquisition of these mutations. Additionally, a family with OSCS is described segregating a germline mutation in WTX and manifesting a lethal phenotype in males. One male from this family had bilateral multifocal nephrogenic rests at autopsy.
RESULTS: In one of the four tumours the WTX mutation was present in both tumour and rest tissue indicating it had arisen early in tumour development. In the remaining three tumours, the WTX mutation was present in the tumour only indicating late acquisition of these mutations.
CONCLUSIONS: These data indicate that WTX mutations can arise both early and late in Wilms tumour development. WTX mutations may predispose to nephrogenic rest development rather than Wilms tumour per se.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20679664     DOI: 10.1136/jmg.2010.080663

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  13 in total

1.  β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors.

Authors:  Peter E Clark; Dina Polosukhina; Harold Love; Hernan Correa; Cheryl Coffin; Elizabeth J Perlman; Mark de Caestecker; Harold L Moses; Roy Zent
Journal:  Am J Pathol       Date:  2011-10-08       Impact factor: 4.307

2.  The WTX tumor suppressor regulates mesenchymal progenitor cell fate specification.

Authors:  Annie Moisan; Miguel N Rivera; Sutada Lotinun; Sara Akhavanfard; Erik J Coffman; Edward B Cook; Svetlana Stoykova; Siddhartha Mukherjee; Jesse A Schoonmaker; Alexa Burger; Woo Jae Kim; Henry M Kronenberg; Roland Baron; Daniel A Haber; Nabeel Bardeesy
Journal:  Dev Cell       Date:  2011-05-17       Impact factor: 12.270

3.  The General Expression Analysis of WTX Gene in Normal and Cancer Tissues.

Authors:  Yao-Yao Zhang; Qi-Ming Wang; Hui-Lin Niu; Xia Liu; Qing-Ling Zhang
Journal:  Pathol Oncol Res       Date:  2016-12-28       Impact factor: 3.201

Review 4.  Inactivation of X-linked tumor suppressor genes in human cancer.

Authors:  Runhua Liu; Mandy Kain; Lizhong Wang
Journal:  Future Oncol       Date:  2012-04       Impact factor: 3.404

Review 5.  Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.

Authors:  Vicki Huff
Journal:  Nat Rev Cancer       Date:  2011-01-20       Impact factor: 60.716

6.  The WTX tumor suppressor enhances p53 acetylation by CBP/p300.

Authors:  Woo Jae Kim; Miguel N Rivera; Erik J Coffman; Daniel A Haber
Journal:  Mol Cell       Date:  2012-01-26       Impact factor: 17.970

Review 7.  WTX R353X mutation in a family with osteopathia striata and cranial sclerosis (OS-CS): case report and literature review of the disease clinical, genetic and radiological features.

Authors:  Anna Maria Zicari; Luigi Tarani; Daniela Perotti; Laura Papetti; Francesco Nicita; Natascia Liberati; Alberto Spalice; Guglielmo Salvatori; Federica Guaraldi; Marzia Duse
Journal:  Ital J Pediatr       Date:  2012-06-20       Impact factor: 2.638

Review 8.  The yin and yang of kidney development and Wilms' tumors.

Authors:  Peter Hohenstein; Kathy Pritchard-Jones; Jocelyn Charlton
Journal:  Genes Dev       Date:  2015-03-01       Impact factor: 11.361

9.  Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors.

Authors:  Dina Polosukhina; Harold D Love; Hernan Correa; Zengliu Su; Kimberly B Dahlman; William Pao; Harold L Moses; Carlos L Arteaga; Harold N Lovvorn; Roy Zent; Peter E Clark
Journal:  Mol Oncol       Date:  2017-03-15       Impact factor: 6.603

10.  Wilms tumor in patients with osteopathia striata with cranial sclerosis.

Authors:  Alicia Bach; Jingyi Mi; Matthew Hunter; Benjamin J Halliday; Sixto García-Miñaúr; Francesca Sperotto; Eva Trevisson; David Markie; Ian M Morison; Marwan Shinawi; Daniel N Willis; Stephen P Robertson
Journal:  Eur J Hum Genet       Date:  2020-09-02       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.